Curriculum vitae Chiara Riganti, MD

Personal details

Born in Torino, Italy, on 14 January 1977
Nationality: Italian
Email: chiara.riganti@unito.it;
Website: http://chiarariganti.wordpress.com/
ORCID ID: 0000-0001-9787-4836; Scopus ID: 6602480015; Researcher ID: K-1207-2016

Educations

- **2002:** graduated (110/110 cum laude and honors) in Medicine at University of Torino.
- **2006**: post-degree medical Specialization in Clinical Biochemistry (70/70 cum laude and honors), University of Torino

Professional experiences and current position

- **2006-2016** assistant professor of Biochemistry, Dept. of Genetics, Biology and Biochemistry/Dept. of Oncology, University of Torino
- **2010**: visiting scientist at Institut Cochin (Prof. Pierre-Olivier Couraud), Universitè Renè Descartes, Paris, France
- **2011** and **2013:** visiting professor, at Weizmann Institute of Science (Dept. of Molecular Genetics; prof. Menachem Rubinstein), Rehovot, Israel
- **2016-2021:** associate professor of Biochemistry at the School of Medicine, Dept. of Oncology, University of Torino
- **2021-today**: full professor of Biochemistry at the School of Medicine, Dept. of Oncology, University of Torino
-**2016-present**: Deputy Director, Interdepartmental Center G. Scansetti for the study of asbestos and nanoparticle toxicity", University of Torino

***Participation to Directive Boards of Scientific Societies and/or Institutions*:**

-2019-2021: member of the Directive Board of the AICC (Italian Association for Cell Cultures)/ECTS (European Tissue Culture Society)

Honors

- **2005**: SIB (Society of Italian Biochemistry) Medal for young investigators
- **2011**: De Benedetti–Cherasco Foundation Award (Best cooperative project with The Weizmann Institute of Science)
- **2011**: AICC/ETCS (Association of Italian Cell Culture/European Tissue Culture Society) award for senior researchers
- **2017:** finalist, "Gianni Bonadonna Prize for the new Development in Oncology"
- **2017**: Outstanding Achievements in Oncology Award, 22nd World Congress on Advances in Oncology
- **2020:** NESIN Award (New Science Inventions International Research Awards) related to the publication doi: 10.1016/j.bbamcr.2020.118824

Teaching activity:

- **2007-present**: lectures of Biochemistry at School of Medicine, University of Torino; tutor in the PhD program in Molecular Medicine, University of Torino.
Supervisor of 4 bachelor students, 13 master students, 10 PhD students, 12 post-doc research fellows.
She hosted 6 research fellows (from 4 weeks to 4 years in International Exchange programs: ERACOL; ERANET1; ERANET2).

Research main topics

-Metabolic bases of of chemo-resistance and immuno-resistance/immune-escape in solid tumor
-Cross talk between tumor and tumor immune-microenvironment that induce resistance to chemotherapy, immunetherapy/immune-surveillnace and environmental stress
- Nanoparticle-based approach to circumvent chemoresistance and immunoresistance in preclinical oncological models.

***6 Main projects as PI*:**
1) **2018-2021:**
Project title: STRATAGEM- New diagnostic and therapeutic tools against multidrug resistant tumors
Source: EU Framework Programme Horizon 2020-Cost Action-CA CA17104
2) **2019-2023:**
Project title: Tipping the balance between ABCB1/ABCC1 and ABCA1: a new approach to reverse chemo-immuno-resistance in solid tumors
Source: AIRC (Italian Association for Cancer Research; IG21408- "Investigator Grant 2018" program)
3) **2015-2018:**
Project title: Dissecting the endoplasmic reticulum-mitochondria network to reverse chemo-immunoresistance of cancer cells
Source: AIRC (Italian Association for Cancer Research; IG2014- "Investigator Grant 2014" program)
4) **2013-2016:**
Project title: Optimization of the oncological therapy: new drugs against Multidrug Resistance
Source: "Italian Ministry of University and Scientific Research – Program Future in Research for young investigators" (FIRB 2012)
5) **2011-2014:**
Project title: A new pharmacological strategy to contemporarily reverse chemo- and immuno-resistance in human tumors
Source: AIRC (Italian Association for Cancer Research; MFAG- "My First AIRC Grant" program)
6) **2013**:
Project title: New strategies against multidrug resistance in primary and metastatic bone tumors"
Source: Universitè Franco-Italienne, Program Galileo 2012-2013

Bibliometry (2002-present) (*www.scopus.com*)
- **203** papers on indexed-journals subjected to peer-review (first author: 36; last author: 58; H-index = 45)
- **1** book chapter + **1** book edition
- **5** patents (2 national + 3 international patents)
-21 invited lectures at international meetings

Top 5 publications as last author
(Full publication list is available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=riganti+C)

1) Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, Tabbò F, Cartia CF, Passone E, Comunanza V, Ardissone F, Ruffini E, Bussolino F, Righi L, Novello S, Di Maio M, Papotti M, Scagliotti GV, **Riganti C**. Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma.
J Thor Oncol 2019, 14(8):1458-1471 ***(IF = 15.609)***
2) Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-ellatef Abd-elrahman GEF, Massaia M, Donadelli M, Rubinstein M, **Riganti C***, Kopecka J*.
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
J Exp Clin Cancer Res 2018; 37:286. (***IF =11.161***3) * *co-last author*
3) Castella B[§], Kopecka J[§], Sciancalepore P, Mandili G, Foglietta M, Mitro N, Caruso D, Novelli F, **Riganti C***, Massaia M*.
Mechanisms of phosphoantigen release and Vγ9Vδ2 T-cell activation by dendritic cells.
Nat Commun 2017, 8:15663 (***IF = 14.919)*** * *co-last author*
4) Salaroglio IC, Panada E, Moiso E, Buondonno I, Provero P, Rubinstein M, Kopecka J, **Riganti C**.
PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. ***Mol Cancer*** 16:e91, 2017 ***(IF = 27.401)***
5) Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, Castella B, Gazzano E, Ghigo D, Rizzo AM, **Riganti C**.
Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition.
Mol Cancer 2013; 12 (1):e137 ***(IF = 27.401)***